Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Cost of Revenue of $32000.0 for Q1 2026, down 27.27% year-over-year from $44000.0 in Q1 2025, and down 37.25% quarter-over-quarter from $51000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Cost of Revenue for 5 consecutive years, with $32000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue fell 27.27% year-over-year to $32000.0; the TTM figure through Mar 2026 stood at $178000.0 (down 16.82% YoY), while the FY2025 annual figure was $190000.0, down 6.86% from the prior year.
- Cost of Revenue declined to $32000.0 in Q1 2026 per OBIO's latest filing, from $51000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $68000.0 in Q3 2024 and bottomed at $32000.0 in Q1 2026.
- Historically, Cost of Revenue has averaged $48411.8 across 5 years, with a median of $47000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cost of Revenue surged 65.85% — and 2025, when it dropped 27.94%.
- Orchestra BioMed Holdings' Cost of Revenue stood at $53000.0 in 2022, then dropped by 11.32% to $47000.0 in 2023, then climbed by 23.4% to $58000.0 in 2024, then dropped by 12.07% to $51000.0 in 2025, then slumped by 37.25% to $32000.0 in 2026.
- Business Quant data shows OBIO's Cost of Revenue at $32000.0 in Q1 2026, $51000.0 in Q4 2025, and $49000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 25,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25,000.00 |
| Mar 31, 2026 | 32,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 42,000.00 |